HealthCap

HealthCap is a European venture capital firm specializing in life sciences investments. Founded in 1996, the firm has raised eight funds and invested in over 130 companies, with more than 45 public offerings and numerous trade sales. HealthCap focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative, change clinical practice, and improve the lives of patients suffering from these conditions. The firm's portfolio companies have developed more than 30 pharmaceutical products and over 50 medical devices, treating millions of patients worldwide. HealthCap's investment strategy emphasizes responsible and sustainable approaches, contributing to the United Nations Sustainable Development Goals of ensuring healthy lives and promoting well-being for all at all ages, and fostering innovation through resilient infrastructure and sustainable industrialization. The team combines venture capital investing experience with expertise in scientific research, drug development, clinical practice, investment banking, and industry management. HealthCap's offices are located in Stockholm, Sweden, and Lausanne, Switzerland.

HealthCap's portfolio includes companies such as Oncorena, a biotech firm developing novel targeted anti-cancer therapies based on antibody-drug conjugates; Ariceum Therapeutics, which develops novel targeted radiopharmaceuticals for cancer treatment; and HelloBetter, a provider of digital therapeutics and online courses to prevent and treat mental illnesses. The firm's investments span various sectors within life sciences, including biotechnology, medical technology, diagnostics, therapeutics, and digital health. HealthCap's commitment to fostering innovation in healthcare aims to make a significant impact on patient outcomes and societal health.

HealthCap is a signatory of the Principles for Responsible Investment and actively manages environmental, social, and governance (ESG) matters throughout the investment process. The firm contributes to the United Nations Sustainable Development Goals by investing in breakthrough therapies for diseases with significant unmet medical needs and supporting the development and scaling of high-potential research ventures. The team comprises professionals with broad expertise, spanning medicine, finance, and biochemistry, dedicated to challenging current medical paradigms to explore new ways of treating or curing diseases, significantly improving quality of life.